Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Receivables (2016 - 2025)

Adma Biologics' Receivables history spans 13 years, with the latest figure at $158.4 million for Q4 2025.

  • For Q4 2025, Receivables rose 216.86% year-over-year to $158.4 million; the TTM value through Dec 2025 reached $158.4 million, up 216.86%, while the annual FY2025 figure was $158.4 million, 216.86% up from the prior year.
  • Receivables reached $158.4 million in Q4 2025 per ADMA's latest filing, up from $137.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $158.4 million in Q4 2025 to a low of $15.4 million in Q1 2021.
  • Average Receivables over 5 years is $48.8 million, with a median of $29.3 million recorded in 2021.
  • Peak YoY movement for Receivables: tumbled 45.74% in 2022, then soared 264.38% in 2025.
  • A 5-year view of Receivables shows it stood at $28.6 million in 2021, then crashed by 45.74% to $15.5 million in 2022, then skyrocketed by 76.85% to $27.4 million in 2023, then surged by 82.34% to $50.0 million in 2024, then surged by 216.86% to $158.4 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Receivables are $158.4 million (Q4 2025), $137.7 million (Q3 2025), and $109.7 million (Q2 2025).